Read
- Planetary alignment peaks with celestial show this weekend
- UK fighters escort Pakistan plane to airport, two arrests
- Judge rules against 'America's toughest sheriff' in racial profiling lawsuit
- Sixth night of violence in Sweden, but police say capital calmer
|
- Justice Department defends journalist email search
Reuters Photojournalism
Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography. See more | Photo caption
Sponsored Links
EU drugs agency has "no new concerns" about GSK's flu shot
A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008.
Credit: Reuters/Toby Melville (BRITAIN)
LONDON |
LONDON (Reuters) - European drugs regulators said on Friday that evidence suggesting a link between GlaxoSmithKline's Pandemrix flu vaccine and a sleeping disorder called narcolepsy is "insufficient" and does not lead to any new concerns.
Pandemrix was designed to protect against the H1N1 pandemic flu which spread around the world in 2009 and 2010. At least 30.8 million people in Europe were vaccinated with it during the pandemic.
The European Medicines Agency (EMA) began a review of the vaccine's safety in 2010 after Finnish researchers presented evidence suggesting it might be linked to a rise in cases of narcolepsy, a rare condition which causes a person to fall asleep suddenly and unexpectedly.
"After careful consideration, the (committee) concluded that the data presented by the Finnish researchers are preliminary and that the evidence presented so far is insufficient to allow conclusions to be drawn," EMA said in a statement.
(Reporting by Kate Kelland)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Follow Reuters